NDA 019886 · Pfizer
Synarel
Nafarelin Acetate · Nasal
NovelLast checked: Nov 20, 2026Latest source record: Nov 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Feb 13, 1990
Approved uses
2
Original approval plus efficacy supplements
Registered trials
10
1 Phase 3, 3 recruiting
FAERS reports
273
225 serious, 9 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 5, 2026.
INDICATIONS AND USAGE FOR CENTRAL PRECOCIOUS PUBERTY (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. INDICATIONS AND USAGE FOR ENDOMETRIOSIS (For Central Precocious Puberty, See Reverse Side ) SYNAREL is indicated for management of endometriosis, including pain relief and reduction of endometriotic lesions. Experience with SYNAREL for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 24, 1998 Supplement 13 · Efficacy LetterReview
- Feb 13, 1990 Original approval · Type 1 - New Molecular Entity
1 products under this application
- SYNAREL · NAFARELIN ACETATE EQ 0.2MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nafarelin" as an intervention, any sponsor and status, largest first.
- Short Versus Long Protocol for IVF and IVF+ICSIPivotal-lookingCompleted
Peter Hornnes, MD, DMScAcademic, hospital or other
NCT00756028 · 1,099 participants · Start Jan 2009 · Primary completion Dec 2014
Drug: Patients receiving short protocol IVF/ICSI-treatment.; Long protocol · For: Infertility; Ovarian Hyperstimulation Syndrome; Quality of Life and 1 more
Sites: Dronninglund, Denmark; Hvidovre, Denmark
- Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI CyclesPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06150703 · 652 participants (planned) · Start Jun 27, 2024 · Primary completion Sep 2027
Drug: Ovulation induction with hCG + Luteal phase support with vaginal progesterone; Ovulation triggering by Triptorelin + Luteal phase support by Nafarelin · For: In Vitro Fertilization; ICSI Intracytoplasmic Spermatozoid Injection
Sites: Bondy, France
- Natural Versus HRT Cycles in Frozen Embryo Replacement TreatmentPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00843570 · 159 participants · Start Nov 2009 · Primary completion May 2013
Drug: Nafarelin acetate, Oestradiol Valerate, Progesterone · For: Infertility
Sites: Oxford, United Kingdom · 2 sites in all
- Intranasal Nafarelin For Triggering Oocyte MaturationPivotal-lookingRecruiting
Fundacion DexeusAcademic, hospital or other
NCT06763926 · 154 participants (planned) · Start Oct 14, 2026 · Primary completion Jan 15, 2028
Drug: Subcutaneous Triptorelin; Intranasal nafarelin · For: Fertility Preservation
Sites: Sabadell, Spain; Sant Cugat del Vallès, Spain; Reus, Spain · 5 sites in all
- Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus ProgesteronePivotal-lookingNot yet recruiting
Shaare Zedek Medical CenterAcademic, hospital or other
NCT06870266 · 150 participants (planned) · Start Mar 2025 · Primary completion Mar 2027
Drug: Nafarelin nasal spray; Utrogestan® · For: Ivf; Frozen Embryo Transfer (FET)
- GnRH Agonist for Luteal Phase Support.Pivotal-lookingStatus unknown
Shaare Zedek Medical CenterAcademic, hospital or other
NCT05484193 · 150 participants · Start Jun 8, 2020 · Primary completion Apr 15, 2022
Drug: GnRH agonist; Progesterone · For: Use of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF Cycles
Sites: Jerusalem, Israel
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High RespondersPivotal-lookingStatus unknown
Assaf-Harofeh Medical CenterGovernment (non-federal)
NCT04797338 · 100 participants (planned) · Start Dec 29, 2017 · Primary completion Sep 30, 2021
Drug: Synarel, 0.2 Mg/Inh Nasal Spray; Estrofem and 2 more · For: Pregnancy Early; Miscarriage; Ovarian Hyperstimulation Syndrome
Sites: Be’er Ya‘aqov, Israel
National Center for Complementary and Integrative Health (NCCIH)NIH
NCT00034047 · 50 participants · Start Sep 2002 · Primary completion Aug 2006
Drug: Chinese Products; Nafarelin · For: Endometriosis; Pelvic Pain
Sites: Portland, Oregon · 2 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- ovarian hyperstimulation syndrome48
- dyspnoea19
- ascites18
- condition aggravated13
- diarrhoea13
- headache13
- nausea13
- off label use13
- pain13
- abdominal pain12
- drug ineffective11
- malaise11
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 4 |
| 2008 | 5 |
| 2009 | 5 |
| 2010 | 34 |
| 2011 | 13 |
| 2012 | 12 |
| 2013 | 10 |
| 2014 | 21 |
| 2015 | 13 |
| 2016 | 15 |
| 2017 | 17 |
| 2018 | 14 |
| 2019 | 10 |
| 2020 | 8 |
| 2021 | 13 |
| 2022 | 16 |
| 2023 | 14 |
| 2024 | 16 |
| 2025 | 15 |
| 2026 | 5 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Synarel (Nafarelin Acetate)
2024 spending
$230K
Beneficiaries
15
71 claims
Per beneficiary
$15,316
$377.87 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $364,740 |
| 2021 | $259,542 |
| 2022 | $211,702 |
| 2023 | $203,562 |
| 2024 | $229,747 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- [Nafarelin acetate (Synarel) and thermocoagulation in the treatment of endometriosis].
Palatyski A, Gruszczyska J, Sobkiewicz S · Ginekol Pol 2001 · Clinical Trial, English Abstract
- Efficacy of nafarelin in assisted reproductive technology: a meta-analysis.
Wong JM, Forrest KA, Snabes SZ, et al. · Hum Reprod Update 2001 · Clinical Trial, Comparative Study
- Nafarelin acetate for pituitary suppressions in in-vitro fertilisation cycles--a Singaporean experience.
Loh SK, Leong NK · Singapore Med J 1999 · Clinical Trial, Randomized Controlled Trial
- Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up.
Waller KG, Shaw RW · Fertil Steril 1993 · Clinical Trial, Randomized Controlled Trial
- Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel).
Adamson GD, Heinrichs WL, Henzl MR, et al. · Am J Obstet Gynecol 1997 · Clinical Trial, Research Support, Non-U.S. Gov't
- Nafarelin versus danazol in the treatment of endometriosis.
Rolland R, van der Heijden PF · Am J Obstet Gynecol 1990 · Clinical Trial, Comparative Study
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.